AID SIGNED

Project "AID" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

+-

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Promaton has built the first of its kind fully automated 2D and 3D X-ray analysis and diagnosis solutions. These Artificial Intelligent Dentistry (AID) solutions significantly reduce labour time and costs of dentists. They speed up tasks of dentist, such as X-ray data cleaning, annotation, segmentation, classification and detection of dental structures and diseases with 90%. Competitors’ offerings require annually on the average as much as 18 days of work or €29,000 in labour costs per dentist more. Promaton aims to penetrate first the French, Benelux and Southern Europe dental analysis and diagnosis markets before scaling up to the German and the American markets. It expects to achieve at least a 2% share of the €2b dental X-ray analysis and diagnosis market and to have grown to more than 200 employees by 2027. Thereto, it proposes large manufacturers to integrate its AID solutions with their own software and hardware platforms for dental X-ray analysis and diagnosis and license the AID solutions at €500 per year per client (being practice or dental clinic). In return, these manufacturers are allowed to white label, co-brand, and license the integrated AID solutions to their client base at their own convenient price points. Asking more than €1,000 per dental practice per year, Promaton’s competitors are expected to phase themselves out quickly. During the AID project, Promaton will validate its value proposition and business model (based on fixed or per analysis-diagnosis fee) with Benelux, French and Southern Europe strategic partners. It will benchmark competitive and alternative solutions, consulting renowned members from medical industry and science. It will consolidate the project results in a viable business plan for industrialization of its DL-based innovations. Meanwhile, it will also certify these innovations as medical software devices and file patents to protect their IPR.